RBMS3-AS3 binds competitively to miR-4534, increasing the level of its downstream target vasohibin 1 (VASH1), creating the molecular axis RBMS3-AS3/miR-4534/VASH1, which may play a pivotal role in prostate cancer development and treatment. Here, VASH1 is linked to prostate carcinoma.